FREIBERG CHRISTOPH
No ORCID on file
· 84 papers in corpus
· active 2011
Frequent coauthors
- WOLF SIEGMUND 84
- TRAUTWEIN MARK 84
- BRUDER SANDRA 84
- GREVEN SIMONE 84
- HARRENGA AXEL 84
- OTTO CHRISTIANE 84
- EICKER ANDREA 42
- WILMEN ANDREAS 42
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indicatio…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indicatio…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indicatio…
2011
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indicatio…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indicatio…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indicatio…
2011
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indicatio…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…